Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6 ):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2 ):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20 ):1938–1948. doi:10.1056/NEJMra100138921067385
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C. Understanding the biology of triple-negative breast cancer. Ann Oncol. 2012;23(Suppl 6 ):vi13–vi18. doi:10.1093/annonc/mds18823012296
   PubMedGoogle Scholar
• Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014;15(13 ):e625–e634. doi:10.1016/S1470-2045(14)70364-X25456381
   PubMed Web of Science ®Google Scholar
• Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(suppl 6 ):vi7–vi12. doi:10.1093/annonc/mds18723012306
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4 ):e173–e180. doi:10.1016/S1470-2045(14)71116-725846097
   PubMed Web of Science ®Google Scholar
• Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22 ):5463–5472. doi:10.1002/cncr.2758122544643
   PubMed Web of Science ®Google Scholar
• Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 2013;13(1 ):31–39. doi:10.1016/j.clbc.2012.09.00223098574
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1 ):4429–4434. doi:10.1158/1078-0432.CCR-06-304517671126
   PubMed Web of Science ®Google Scholar
• Li CY, Wang P, Zhang S, Liu Y, Zhang J. Clincopathological features and prognosis of triple-negative breast cancer. Chin J Oncol. 2013;35(6 ):173–181.
   Google Scholar
• Yu F, Zhang XB, Zhang S, Liu JJ, Liu Y, Zhang J. Patterns and risk factors of recurrence in triple-negative breast cancer. Natl Med J China. 2014;94(28 ):2180–2183.
   Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11 ):e493–e503. doi:10.1016/S1470-2045(14)70263-325281468
   PubMed Web of Science ®Google Scholar
• Jezequel P, Loussouarn D, Guerin-Charbonnel C, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015;17:43. doi:10.1186/s13058-015-0550-y25887482
   PubMed Web of Science ®Google Scholar
• Wang XJ, Xiang M, Tao YJ, et al. Application of preoperative neutrophil-to-lymphocyte ratio in the evaluation of prognosis in patients with triple-negative breast cancer. Oncol Prog. 2017;15(6 ).
   Google Scholar
• Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6 ):dju124. doi:10.1093/jnci/dju12424875653
   PubMedGoogle Scholar
• Chen CZ, Lin CQ, Chen DL, et al. The effect and clinical significance of preoperative neutrophil-lymphocyte ratio on the prognosis of triple-negative breast cancer patients. Chin J General Surg. 2017;32(9 ):789–790.
   Google Scholar
• Pistelli M, De Lisa M, Ballatore Z, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015;15:195. doi:10.1186/s12885-015-1204-225884918
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23 ):6212–6222. doi:10.1158/1078-0432.CCR-14-044225271081
   PubMed Web of Science ®Google Scholar
• Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg. 2019;270(1 ):139–146. doi:10.1097/SLA.000000000000266029334554
   PubMed Web of Science ®Google Scholar
• Yang J, Guo X, Wang M, Ma X, Ye X, Lin P. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. Sci Rep. 2017;7(1 ):17166. doi:10.1038/s41598-017-17130-629215037
   PubMedGoogle Scholar
• Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017;15(1 ):221. doi:10.1186/s12967-017-1326-129089030
   PubMed Web of Science ®Google Scholar
• Wang P, Yue W, Li W, et al. Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer. Cancer Manag Res. 2019;11:813–819. doi:10.2147/CMAR.S18589030697073
   PubMed Web of Science ®Google Scholar
• Guo W, Lu X, Liu Q, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9 ):4135–4148. doi:10.1002/cam4.228131197958
   PubMed Web of Science ®Google Scholar
• Song W, Wang K, Zhong F, Fan YW, Peng L, Zou SB. Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma. Oncotarget. 2016;7(49 ):81830. doi:10.18632/oncotarget.1324427833084
   PubMedGoogle Scholar
• Zou ZY, Liu HL, Ning N, Li SY, Du XH, Li R. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016;11(3 ):2241–2248. doi:10.3892/ol.2016.421626998156
   PubMed Web of Science ®Google Scholar
• Liu J, Dai Y, Zhou F, et al. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urol Oncol. 2016;34(11 ):484 e1–e8. doi:10.1016/j.urolonc.2016.05.024
   PubMed Web of Science ®Google Scholar
• Azab BN, Bhatt VR, Vonfrolio S, et al. Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg. 2013;206(5 ):764–770. doi:10.1016/j.amjsurg.2013.03.00723866764
   PubMed Web of Science ®Google Scholar
• Xuan Q, Yang Y, Ji H, et al. Combination of the preoperative albumin to globulin ratio and neutrophil to lymphocyte ratio as a novel prognostic factor in patients with triple negative breast cancer. Cancer Manag Res. 2019;11:5125–5131. doi:10.2147/CMAR.S19532431213922
   PubMed Web of Science ®Google Scholar
• Dai D, Chen B, Tang H, et al. Nomograms for predicting the prognostic value of pre-therapeutic CA15-3 and CEA serum levels in TNBC patients. PLoS One. 2016;11(8 ):e0161902. doi:10.1371/journal.pone.016190227561099
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two Phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27 ):2959. doi:10.1200/JCO.2013.55.049125071121
   PubMed Web of Science ®Google Scholar
• Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;8:1698–1704. doi:10.1093/annonc/mdv239
   Google Scholar